Seattle scientists launch $95 million AI biology effort
admin The failure of Ultragenyx’s GTX-102 is a profound blow to the Angelman syndrome community, which...
Health
Recipients of gene-edited pig kidneys successfully receive human organs
The announcement made by eGenesis on Thursday evening represents a watershed moment in the field...
Ionis Pharmaceuticals Wins FDA Approval for Zanvastro, the First Disease-Modifying Therapy for Alexander Disease.
The U.S. Food and Drug Administration on Thursday granted landmark approval to Ionis Pharmaceuticals for...
Beyond the Field: New Cardiovascular Guidelines Address the Life-and-Death Stakes Facing America’s Tactical Athletes
Tactical athletes may be the most important professionals you’ve never heard of, serving as the...
Navigating the Vaccine Divide: How One Massachusetts Pediatric Practice Becomes a ‘Practice of Last Resort’ Amid a National Trust Crisis
The late afternoon sun filtered through the windows of Middleboro Pediatrics in Lakeville, Massachusetts, casting...
The Curious Case of Abivax: Why the $20 Billion Ulcerative Colitis Payday Remains Elusive in a Red-Hot M&A Market.
In the high-stakes theater of biotechnology, where multi-billion dollar acquisitions are often the climax of...
The Great Decline: Unpacking the Unprecedented Drop in Global Overdose Deaths and the Fragile Future of Harm Reduction
From 2021 to 2023, the United States was gripped by a public health catastrophe of...
How a former ARPA-H director’s startup is tackling AI’s ‘dumb problems’
The current state of AI in healthcare is characterized by a transition from general-purpose Large...
Ultragenyx Shares Plunge as Pivotal Phase 3 Trial for Angelman Syndrome Therapy Fails to Meet Primary Endpoint.
The biotech industry and the rare disease community were dealt a staggering blow on Wednesday...
ARPA-H funds biotechs working on custom RNA therapies
The deal finalized by Roche involves a sophisticated tri-specific antibody platform designed to engage three...
